Enanta Pharmaceuticals (NASDAQ:ENTA) is set to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.03 per share for the quarter.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $40.92 million. During the same period in the prior year, the firm earned $0.61 earnings per share. The business’s quarterly revenue was down 10.0% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ENTA stock opened at $71.77 on Monday. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $106.80. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of 20.62 and a beta of 0.98. The firm’s 50-day moving average price is $83.66.
A number of analysts have commented on ENTA shares. BidaskClub lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 31st. Wolfe Research initiated coverage on Enanta Pharmaceuticals in a report on Friday, May 24th. They issued an “outperform” rating and a $117.00 target price on the stock. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a report on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $109.00.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
See Also: What are CEFs?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.